Showing results (2651-2660 of 2,815) with videos related to
Sort By:
Pageof 282
Nature Communications|October 27, 2017
Resistance to checkpoint blockade therapy through inactivation of antigen presentationMoshe Sade-Feldman, Yunxin J Jiao, Jonathan H Chen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 MonotherapyXue Bai, Jiani Hu, Allison Betof Warner, et al.JAMA Oncology|July 17, 2015
Rapid Intraoperative Molecular Characterization of GliomaGanesh M Shankar, Joshua M Francis, Mikael L Rinne, et al.Nature|September 28, 2017
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomasHezhe Lu, Shujing Liu, Gao Zhang, et al.European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapySarah K Jacques, Janet McKeown, Piyush Grover, et al.Biorxiv : the Preprint Server for Biology|October 4, 2023
Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and TumorSteven M Blum, Daniel A Zlotoff, Neal P Smith, et al.Biorxiv : the Preprint Server for Biology|June 30, 2020
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular ProbesTongqing Zhou, I-Ting Teng, Adam S Olia, et al.Cell Reports|October 22, 2020
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular ProbesTongqing Zhou, I-Ting Teng, Adam S Olia, et al.Blood Advances|April 20, 2022
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concernMaggie Li, Evan J Beck, Oliver Laeyendecker, et al.Journal for Immunotherapy of Cancer|March 5, 2026
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review studyElizabeth M Gaughan, Miso Kim, Ignacio Mendez, et al.Pageof 282